March 7, 2017
Akcea Therapeutics’ Volanesorsen Study Meets Primary Endpoint of Reducing Triglyceride Levels in Patients with Familial Chylomicronemia Syndrome (FCS)
Read More
January 5, 2017
SPINRAZA™ (nusinersen) Approved in U.S. to Treat Broad Range of Patients with Spinal Muscular Atrophy
Read More
X